Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 9/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737070 | 0.88 | PRCP (0.54) | PRCPMAPTSMN1; SMN2POLBPTPN1 | |
| SCHEMBL12184748 | 0.87 | PRCP (0.50) | PRCPMAPTSMN1; SMN2POLBPTPN1 | |
| SCHEMBL14749294 | 0.83 | PRCP (0.47) | PRCPMAPTSMN1; SMN2POLBGRM5 | |
| SCHEMBL14749302 | 0.83 | PRCP (0.48) | PRCPMAPTSMN1; SMN2POLB | |
| SCHEMBL12184228 | 0.83 | PRCP (0.56) | PRCPGRM5ALDH1A1 | |
| SCHEMBL12184137 | 0.83 | PRCP (0.56) | PRCPGRM5ALDH1A1 | |
| SCHEMBL14749421 | 0.81 | PRCP (0.55) | PRCPMAPTSMN1; SMN2POLBPTPN1 | |
| SCHEMBL14749284 | 0.80 | PRCP (0.49) | PRCPMAPTSMN1; SMN2POLBGRM5 | |
| SCHEMBL12184147 | 0.79 | PRCP (0.60) | PRCPMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14737395 | 0.79 | PRCP (0.56) | PRCPSMN1; SMN2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059830-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | PRCP 1/4885MAPT 3765/4885SMN1; SMN2 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.